You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 21, 2024


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for pegvisomant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00017927 ↗ A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome Completed National Institute of Dental and Craniofacial Research (NIDCR) Phase 3 2001-06-01 This study will examine the effect of pegvisomant on growth hormone excess in patients with McCune-Albright syndrome (MAS). Patients with this disease have polyostotic fibrous dysplasia-a condition in which areas of normal bone are replaced with fibrous growth similar to scar tissue, abnormal skin pigmentation (birth marks) and precocious (early) puberty. About 10 percent of patients have excess growth hormone (GH). GH stimulates the production of another hormone called insulin-like growth factor 1 (IGF-1). Together, GH and IGF-1 affect bone growth. The excess of these hormones in MAS can cause overgrowth of the bones of the face, hands and feet, excess sweating, or increased height. Pegvisomant is a synthetic drug that binds to cell receptors where GH would normally bind, thus preventing the naturally occurring hormone from stimulating IGF-1 and bone growth as it normally would. This study will see if pegvisomant will reduce blood levels of IGF-1 and mitigate the effects of growth hormone excess, including bone pain, bone turnover, hand and foot swelling and sweating, and abnormal levels of related hormones. Patients who were screened for polyostotic fibrous dysplasia and MAS under NIH protocol 98-D-0145 and were found to have MAS with excess growth hormone are eligible for this 36-week study. The screening protocol includes a history and physical examination, blood and urine tests, hearing, eye and dental examinations, pain and physical function evaluations, endocrine and bone screening tests, various bone imaging studies, including magnetic resonance imaging (MRI) and computed tomography (CT) scans and bone biopsy in patients over 6 years old. Participants in the current study will receive daily injections of either pegvisomant or placebo (an inactive substance) for 12 weeks, followed by a 6-week "washout" period with no drug. Then, patients who received placebo will be switched, or "crossed over," to receive pegvisomant for another 12 weeks, and those who received pegvisomant will receive placebo. This will be followed by another 6-week washout period. The drug and placebo will be injected under the skin, similar to insulin injections. Blood and urine tests will be done at the beginning of the study and repeated every 6 weeks until the study ends.
NCT00068029 ↗ Pegvisomant And Sandostatin LAR Combination Study Completed Pfizer Phase 4 2003-10-01 The purpose of this study is to compare the safety and tolerability of combination therapy with Sandostatin LAR plus Pegvisomant to that of Sandostatin LAR alone or Pegvisomant alone.
NCT00068042 ↗ A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed Pfizer Phase 4 2003-04-01 The purpose of the study is to determine if Pegvisomant is more efficacious than Sandostatin LAR Depot in normalizing IGF-I levels in treatment naive patients with acromegaly.
NCT00143416 ↗ Long Term Study With B2036-PEG Completed Pfizer Phase 3 2004-04-01 Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
NCT00151437 ↗ Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed Pfizer Phase 4 2004-11-01 The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.
NCT00383708 ↗ Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients Completed Ipsen Phase 3 2006-10-01 The main aim of this study is to assess the efficacy of the co-administration of lanreotide Autogel 120 mg (administered via deep sub-cutaneous injections every 28 days) and pegvisomant (administered at 40 to 120 mg per week via sub-cutaneous injection given once or twice a week) on IGF-1 levels over 28 weeks in acromegalic patients. The primary endpoint will be the percentage of acromegalic patients with normalised (age and sex adjusted) IGF-1 level at the end of the co-treatment period.
NCT00468624 ↗ Effect of Pegvisomant on GH/IGF-I Relationship in GHD Terminated The Christie NHS Foundation Trust N/A 2004-12-01 Approximately 50% of middle-aged patients with severe AGHD have a normal age-related serum IGF-I. It remains unclear if in these individuals serum IGF-I is GH dependent or independent. This study compared the relationship between GH and serum IGF-I in two cohorts of male patients with severe AGHD; one with normal and the other with subnormal age-related serum IGF-I values. The GH receptor antagonist - pegvisomant was be used to specifically inhibit GH action and the changes in markers of the GH axis, such as serum IGF-I, IGFBP-3, GH and GHBP were measured.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for pegvisomant

Condition Name

Condition Name for pegvisomant
Intervention Trials
Acromegaly 16
Insulin Resistance 2
Metabolic Syndrome 1
Healthy Volunteers 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for pegvisomant
Intervention Trials
Acromegaly 18
Insulin Resistance 4
Dwarfism, Pituitary 2
Endocrine System Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for pegvisomant

Trials by Country

Trials by Country for pegvisomant
Location Trials
United States 24
Canada 13
Germany 6
Brazil 6
United Kingdom 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for pegvisomant
Location Trials
California 5
Maryland 3
Oregon 2
Virginia 2
North Carolina 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for pegvisomant

Clinical Trial Phase

Clinical Trial Phase for pegvisomant
Clinical Trial Phase Trials
Phase 4 9
Phase 3 5
Phase 2 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for pegvisomant
Clinical Trial Phase Trials
Completed 19
Unknown status 4
Recruiting 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for pegvisomant

Sponsor Name

Sponsor Name for pegvisomant
Sponsor Trials
Pfizer 9
University of Aarhus 3
Erasmus Medical Center 2
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for pegvisomant
Sponsor Trials
Other 22
Industry 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.